A Phase I, skin safety study with SKE-18 1% cream in healthy Japanese participants

Sato Pharmaceutical Co., Ltd.0 个研究点目标入组 25 人开始时间: 2024年3月28日最近更新: 2024年7月30日

试验速览

暂无简介。

•Healthy Japanese adult males aged 18 to 40 years at the time of signing the Informed Consent Form
•Subjects with BMI (body mass index) of >= 18.5 to < 25.0 at screening
•Subjects who are considered by the investigator as acceptable for inclusion in the study as judged from the results of observation and inspection upon screening and admission
•Subjects who received full explanations regarding the objective of the study, details of the study and the study drug and provided voluntary written informed consent

•Subject with a medical history of drug allergy
•Subjects with a medical history of food allergy
•Subjects with a medical history (heart, liver, kidney, lung, blood diseases, etc.) that is considered ineligible for the study
•Subjects with a medical history of contact dermatitis, such as adhesive tape dermatitis, or mechanical urticaria
•Subjects with a medical history of photosensitivity
•Subjects considered ineligible for the study by the investigator

Safety

未报告次要终点

发起方